HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Julio Rosenstock Selected Research

Vomiting

12/2023Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
11/2023Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
10/2021Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
1/2021Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
1/2021Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
11/2019Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
1/2019Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
1/2018Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.
11/2016Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
8/2014Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Julio Rosenstock Research Topics

Disease

214Type 2 Diabetes Mellitus (MODY)
05/2024 - 04/2002
63Hypoglycemia (Reactive Hypoglycemia)
05/2024 - 11/2003
58Body Weight (Weight, Body)
03/2024 - 02/2006
35Weight Loss (Weight Reduction)
11/2023 - 05/2005
25Weight Gain
01/2023 - 06/2004
20Type 1 Diabetes Mellitus (Autoimmune Diabetes)
04/2024 - 01/2005
20Nausea
12/2023 - 02/2006
17Heart Failure
04/2024 - 07/2012
15Cardiovascular Diseases (Cardiovascular Disease)
03/2024 - 07/2015
14Vomiting
12/2023 - 01/2011
14Overweight
01/2023 - 11/2003
13Obesity
11/2023 - 03/2005
12Infections
01/2019 - 06/2012
11Stroke (Strokes)
01/2024 - 11/2016
10Myocardial Infarction
01/2024 - 11/2016
9Kidney Diseases (Kidney Disease)
12/2023 - 09/2015
9Hyperglycemia
10/2022 - 07/2010
8Chronic Renal Insufficiency
03/2024 - 01/2019
7Albuminuria
01/2023 - 09/2015
7Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
01/2022 - 03/2015
6Body Weight Changes
01/2024 - 02/2006
6Diarrhea
11/2023 - 01/2011
6Pancreatitis
10/2021 - 01/2017
5Prediabetic State (Prediabetes)
01/2022 - 07/2010
5Insulin Resistance
01/2021 - 10/2006
5Urinary Tract Infections (Urinary Tract Infection)
01/2018 - 06/2012
4Injection Site Reaction
11/2020 - 03/2013
4Diabetes Mellitus
01/2020 - 05/2002
4Edema (Dropsy)
07/2012 - 03/2006
3Constipation
12/2023 - 01/2011
3Hypercholesterolemia
01/2023 - 07/2010
3Pain (Aches)
11/2017 - 08/2004
3Neuralgia (Stump Neuralgia)
11/2017 - 09/2008
3Dizziness (Lightheadedness)
12/2014 - 08/2004
3Peripheral Nervous System Diseases (PNS Diseases)
02/2013 - 08/2004
2Diabetic Cardiomyopathies
04/2024 - 01/2023

Drug/Important Bio-Agent (IBA)

90Insulin (Novolin)FDA Link
05/2024 - 04/2002
69Glucose (Dextrose)FDA LinkGeneric
03/2024 - 11/2003
58Metformin (Glucophage)FDA LinkGeneric
12/2023 - 05/2005
52Insulin Glargine (Lantus)FDA Link
11/2023 - 11/2003
29Glucagon-Like Peptide-1 ReceptorIBA
02/2024 - 10/2009
22LinagliptinIBA
01/2024 - 08/2012
20Hypoglycemic Agents (Hypoglycemics)IBA
05/2024 - 10/2004
20Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
05/2024 - 09/2002
19semaglutideIBA
02/2024 - 11/2016
19Glucagon-Like Peptide 1 (GLP 1)IBA
12/2023 - 07/2009
19lixisenatideIBA
01/2022 - 09/2013
19Exenatide (Byetta)FDA Link
01/2022 - 05/2005
15empagliflozinIBA
04/2024 - 07/2014
15Sodium-Glucose Transporter 2 InhibitorsIBA
01/2023 - 07/2012
14Glucagon-Like Peptide-1 Receptor AgonistsIBA
03/2024 - 04/2014
14Sodium-Glucose Transport ProteinsIBA
01/2021 - 06/2012
13LiraglutideFDA Link
11/2023 - 07/2009
12LipidsIBA
11/2023 - 03/2005
11omega-Chloroacetophenone (Mace)IBA
01/2024 - 01/2019
11glimepiride (Amarel)FDA LinkGeneric
01/2024 - 08/2012
10SodiumIBA
03/2024 - 07/2012
10CreatinineIBA
01/2023 - 06/2012
9InsulinsIBA
05/2024 - 04/2012
9Blood Glucose (Blood Sugar)IBA
05/2024 - 03/2010
8Dipeptidyl-Peptidase IV InhibitorsIBA
01/2024 - 01/2008
8insulin degludecIBA
11/2023 - 03/2011
8AlbuminsIBA
01/2023 - 09/2015
8dapagliflozinIBA
01/2020 - 07/2012
7efpeglenatideIBA
12/2023 - 01/2019
7(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA
01/2023 - 07/2013
7LDL CholesterolIBA
10/2022 - 08/2008
7Pioglitazone (Actos)FDA Link
11/2019 - 10/2006
7saxagliptinFDA Link
01/2019 - 11/2010
6Sitagliptin Phosphate (Januvia)FDA Link
11/2023 - 10/2006
6insulin aspart protamine drug combination 30:70 insulin aspartIBA
01/2023 - 10/2004
6rGLP-1 proteinIBA
11/2021 - 10/2009
6CanagliflozinIBA
01/2019 - 06/2012
6Colesevelam Hydrochloride (Welchol)FDA Link
07/2012 - 08/2008
5tirzepatideIBA
01/2024 - 01/2021
5Hemoglobins (Hemoglobin)IBA
11/2023 - 07/2010
5Peptides (Polypeptides)IBA
11/2023 - 01/2021
5Insulin Aspart (NovoLog)FDA Link
11/2023 - 10/2004
5insulin icodecIBA
11/2023 - 11/2020
52,4-thiazolidinedione (thiazolidinedione)IBA
01/2018 - 09/2002
4SymportersIBA
03/2024 - 09/2015
4Glucagon Receptors (Glucagon Receptor)IBA
12/2023 - 01/2020
4Insulin Lispro (Humalog)FDA Link
11/2023 - 01/2008
4Protamines (Protamine Sulfate)FDA Link
06/2021 - 10/2004
4IncretinsIBA
01/2021 - 05/2005
4LY2605541IBA
01/2014 - 11/2012
4ExuberaFDA Link
03/2010 - 06/2004
4PowdersIBA
03/2010 - 02/2007
3Aldehyde Reductase (Aldose Reductase)IBA
04/2024 - 01/2023
3Glucagon (Glukagon)FDA Link
02/2024 - 10/2022
3SuspensionsIBA
10/2020 - 01/2008
3insulin glulisineFDA Link
08/2016 - 10/2004
3Short-Acting InsulinIBA
01/2016 - 09/2013
3Isophane Insulin (NPH Insulin)FDA Link
11/2012 - 11/2004
3oxidized low density lipoproteinIBA
07/2012 - 07/2010
3VildagliptinIBA
01/2008 - 02/2007

Therapy/Procedure

81Therapeutics
03/2024 - 09/2002
62Glycemic Control
01/2024 - 04/2002
17Injections
11/2023 - 04/2002
4Subcutaneous Injections
01/2021 - 04/2002